4[1]Pauwels RA,Buist AS,Calverley PM,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease:NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summery.Am J Respir Crit Care Med,2001;163:1256～1276
5[2]Johnson M,Rennard S.Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.Chest,2001;120:258～270
6[3]Moore RH,Khan A,Dickey BF.Long-acting inhaled β2-agonists in asthma Therapy.Chest,1998;113:1095～1108
7[4]Cazzola M,Calderaro F,Califano C,et al.Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease.Eur J Clin Pharmacol,1999;54:829～833
8[5]Lai CK,Chan CH,Ho SS,et al.Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.Chest,1995;108:36～40
10[7]Rasche K,Duchna HW,Lauer J,et al.Obstructive Sleep Apnea and Hypopnea Efficacy and Safety of a Long-Acting beta2-Agonist.Sleep Breath,1999;3:125～130
